Results 11 to 20 of about 93,603 (306)

Psilocybin's Emerging Role in Combating Depressive Disorder

Journal of Education, Health and Sport, 2023
        In this review paper, we delve into the potential applicability of psilocybin - a naturally synthesized psychedelic substance found within select species of fungi, as a prospective avenue for depression treatment.
Anna Jaremek, Joanna Kępa, Norbert Kandefer, Michał Wyszkowski, Aleksandra Grabarczyk, Anna Pawlak, Sylwia Grad, Małgorzata Gregorek, Paweł Gregorek   +8 more
doaj   +1 more source

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression

European Psychiatry, 2022
Introduction The compassionate use of intranasal esketamine is approved in Spain for treatment-resistant depression (TRD). Objectives The objective of the study is to assess the clinical stability in the medium-term follow-up of patients with TRD after
D. Hernandez Huerta, A. De Santiago Diaz, C. Rodriguez Gomez-Carreño, M.A. Abril Garcia, F. Toledo Romero, A. Guerrero Morcillo, C.J. Martinez Pastor, M. Vega Piñero   +7 more
doaj   +1 more source

Clinical efficacy and tolerability of Esketamine: a case series

European Psychiatry, 2022
Introduction Esketamine is a novel antidepressant approved by the FDA in 2019 in the form of an intranasal spray, recommended for Treatment-Resistant Depression (TRD).
C. Passani, N. Ragone, C.M. Congedo, B. Barbini, R. Zanardi, M.C. Cavallini, C. Colombo   +6 more
doaj   +1 more source

Effects of psilocybin-assisted therapy on treatment-resistant depression

European Psychiatry, 2021
Introduction Major depressive disorder is a highly prevalent clinical condition, affecting more than 300 million individuals worldwide. About 1/3 of patients with MDD fail to achieve remission despite treatment with multiple antidepressants and are ...
A. Fraga, D. Esteves-Sousa, J. Facucho-Oliveira, M. Albuquerque, M. Costa, P. Espada Dos Santos, N. Moura, A. Moutinho   +7 more
doaj   +1 more source

Is treatment resistant depression a different subtype of depression?

European Psychiatry, 2021
Major depression is a serious, disabling, often chronic or recurrent mental disorder affecting over 350 million people worldwide. Treatment of major depression is now conceptualized as proceeding through three phases: the acute phase, the continuation ...
A. Fiorillo
doaj   +1 more source

Use of pharmacotherapies for treatment resistant depression in finland: A nationwide cohort study

European Psychiatry, 2021
Introduction There is a lack of knowledge on utilized pharmacotherapies for treatment resistant depression (TRD). Objectives To investigate the courses of treatment of TRD.
H. Taipale, M. Lähteenvuo, A. Tanskanen, S. Rannanpää, J. Tiihonen   +4 more
doaj   +1 more source

Patients’ Comprehension of Mindfulness-Based Cognitive Behavioral Therapy in an Outpatient Clinic for Resistant Depression: A Cross-Sectional Study

Frontiers in Psychology, 2019
The current study investigated the comprehension of mindfulness-based cognitive behavioral therapy (MBCT) by patients with resistant depression at the Psychiatry Institute of the Federal University of Rio de Janeiro, Brazil.
Michele F. Rodrigues, Carlos Campos, Luisa Pelucio, Izabel Barreto, Sergio Machado, Jose C. Appolinario, Antonio E. Nardi, Michelle Levitan   +7 more
doaj   +1 more source

Modeling treatment-resistant depression [PDF]

Neuropharmacology, 2011
Depression is a polygenic and highly complex psychiatric disorder that is currently a major burden on society. Depression is highly heterogeneous in presentation and frequently exhibits high comorbidity with other psychiatric and somatic disorders. Commonly used treatments, such as selective serotonin reuptake inhibitors (SSRIs), are not ideal since ...
Benjamin Adam, Samuels, Eduardo David, Leonardo, Reto, Gadient, Amanda, Williams, Jin, Zhou, Denis J, David, Alain Michel, Gardier, Erik H F, Wong, René, Hen   +8 more
openaire   +2 more sources

A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.

PLoS ONE, 2020
ObjectiveThe economic burden of commercially insured patients in the United States with treatment-resistant depression and patients with non-treatment-resistant major depressive disorder was compared using data from the Optum Clinformatics™ claims ...
Gang Li, Ling Zhang, Allitia DiBernardo, Grace Wang, John J Sheehan, Kwan Lee, Johan Reutfors, Qiaoyi Zhang   +7 more
doaj   +2 more sources

Treatment resistant depression

Sri Lanka Journal of Psychiatry, 2018
No abstract ...
D. Ariyasinghe, S. S. Williams
doaj   +1 more source